Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17548263 | 0.89 | NPC1 (0.31) | NPC1 | |
| SCHEMBL17547968 | 0.80 | ALDH1A1 (0.31) | MAPK1DGAT1 | |
| SCHEMBL17548089 | 0.78 | NPC1 (0.41) | POLBMAPTNPC1 | |
| SCHEMBL31748668 | 0.78 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL15808369 | 0.76 | NPC1 (0.32) | MAPTDGAT1NPC1 | |
| SCHEMBL17548097 | 0.76 | DGAT1 (0.34) | KDM4ELMNAPOLBMAPTXBP1 | |
| SCHEMBL19397918 | 0.76 | — | — | |
| SCHEMBL20192621 | 0.76 | — | — | |
| SCHEMBL16920120 | 0.74 | PIK3C2B (0.36) | KDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL16920118 | 0.72 | NPC1 (0.39) | LMNAMAPTRAB9ASMN1; SMN2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| WO-2016031842-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT | 塩野義製薬株式会社 | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAG1 | KDM4E 513/4885LMNA 2984/4885POLB 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.